Immune checkpoint test by luminescence
Cell engineering is an important part of modern basic and translational life science research. At GenScript, we recognize that having strong cell engineering capabilities is critical in ensuring you meet your project milestones. In addition to our award winning gene synthesis services, we are proud to bring you a wide array of cell engineering platforms as well as accompanying technical expertise to help meet your project needs.
|Assay Cell Line Development||CRISPR Cell Line Development||Lentivirus Packaging|
|Service Options||Constitutive/Inducible||Knock-in/Knock-out||Highly customized|
|Production Time||Start from 7 weeks||Start from 3 weeks||Start from 4 weeks|
|Deliverables||Stable Cell Pool/Clone||Stable Cell Pool/Clone||Lentivirus|
Empowered by GenScript’s CellPower™ and GenCRISPR™ services, we can provide cell engineering services from target screening to in vitro & in vivo assay.
Cell engineering is mainly associated with the modifications and alterations of host cells for enhancing the yield and quality of the expressed protein. There are several approaches for altering the cellular processes such as silencing or overexpressing of targeted genes and altering expression of genes using microRNA. Cells are powerful therapeutic agents. Whether they are engineered or in their natural state, cells are increasingly utilized across a range of pathologies. Gene overexpressing and silencing are the major approach for cellular engineering. RNA interference is being used to silence multiple genes of different cellular pathways for optimum productivity of bioengineered proteins. New advanced tools that are currently used for gene editing are zinc finger nucleases, modified meganucleases, hybrid DNA/RNA oligonucleotides, Transcription Activator like (TAL) effector nucleases, and modified Clustered Regularly Interspaced Short Palindrome Repeats (CRISPR)/Cas9. With an expanding array of cell types now under investigation for the treatment of cancer, genetic disorders, infectious diseases, and degenerative disorders, GenScript is fostering cutting-edge research on emerging cellular therapies.
Dr. Theo Roth from Marson Lab, UCSF
He introduces the advantages of a new CRISPR based method that allows for the insertion of large DNA sequences (>1Kb) in primary T cells without a virus.